Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Regulatory & Legal

TITLE:

EMA: EMA updates the list of all products granted access to the PRIME scheme on September

BRIEF:

PRIME is a scheme launched by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier. EMA updates the list of all products granted access to the PRIME scheme on a monthly basis. EMA removes products from the list if they receive a Marketing Authorization Application for them, if they are withdrawn from the scheme or no longer meet the eligibility criteria.

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company